Biotech Values

[poorgradstudent]

I follow MYGN. Luckily, they've had a nice run this year.

The company is receiving revenues from a breast cancer diagnostic test. They are attempting to expand their presence in the "predictive medicine" arena, and today's announcement is along that line. In the clinic, they have an enantiomer of flurbiprofen for alzheimer's disease. Because of my lack of knowledge in the CNS area, I have no substantive comments on this drug's chances, or lack thereof.

If their revenues and expenses stay flat, they have about 3 years of money in the bank.

As for IMGN, i think it is a good short. This company is being used as a retirement vehicle for the CEO, and he has lost all motivation to advance the company independently. He's sold out all his pipeline, and makes these collaborations in an attempt to hopefully get one drug on the market and draw royalties. There is no explosive upside to this company, and I'm convinced that their acumen in the clinic is next to nil.